StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
OKUROnKure Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$2.60▲ 3.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $105.0MShares out 40.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

18
  • 10.8Overnight26.10.08 09:06
    SCHEDULE 13GOwnership#●●●

    OnKure Therapeutics, Inc.

    Coastlands Capital LP and its affiliated entities have filed an agreement regarding the joint filing of Schedule 13D or 13G statements for OnKure Therapeutics, Inc. Coastlands Capital LP has been appointed as the agent and attorney-in-fact for the joint filing process.…more

    $2.60+3.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.23After-hours26.09.24 05:54
    4Ownership

    OnKure Therapeutics, Inc.

    Nicholas A. Saccomano, an insider at OnKure Therapeutics, reported a change in beneficial ownership of company securities as of September 21, 2026. This filing serves as a formal disclosure of the insider's updated equity position via Form 4.…more

    $2.60+3.17%vs prev close
    View filingShare
  • 9.23After-hours26.09.24 05:52
    4Ownership

    OnKure Therapeutics, Inc.

    Insider Jason A. Leverone of OnKure Therapeutics, Inc. filed a Form 4 report regarding a change in beneficial ownership of securities as of September 21, 2026. This filing serves as a standard disclosure of insider transactions and does not involve new share issuance or financial changes.…more

    $2.60+3.17%vs prev close
    View filingShare

17 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.31Pre-market26.08.31 21:00
    #●●●#●●●

    OnKure Therapeutics to Participate in Morgan Stanley Global Healthcare Conference…more

    OnKure Therapeutics announced its participation in the upcoming Morgan Stanley Global Healthcare Conference to hold one-on-one investor meetings. This is a routine investor relations event and does not provide new material information affecting the stock price.…more

    $2.60+3.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.4After-hours26.08.05 05:05

    ●●●●●●●● ●●●●● ●●●●●●

    온큐어 테라퓨틱스는 차세대 PI3Kα 억제제 후보물질인 OKI-345와 OKI-355의 임상시험계획(IND)을 2027년 상반기에 제출할 예정입니다. 현재 약 1억 7,600만 달러의 현금을 보유하여 2029년까지 안정적인 운영 자금을 확보했습니다.…more

    $2.60+3.17%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →